Full Press Release Details
Zymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day.
ZYME
Zymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day
Key Takeaway: Zymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day
Price reaction · baseline $5.94 (2022-10-03 close) · hit after-hours · 1 other ZYME headline(s) in the window, move may be shared
day 0 close
+2.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers